Front Row Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Front Row Advisors’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15	Closed	-$2K	–	923
2023 Q2	$2K	Hold	15	–	–	﹤0.01%	800
2023 Q1	$2K	Hold	15	–	–	﹤0.01%	815
2022 Q4	$2K	Hold	15	–	–	﹤0.01%	780
2022 Q3	$2K	Hold	15	–	–	﹤0.01%	809
2022 Q2	$2K	Hold	15	–	–	﹤0.01%	814
2022 Q1	$2K	Hold	15	–	–	﹤0.01%	852
2021 Q4	$2K	Hold	15	–	–	﹤0.01%	875
2021 Q3	$2K	Hold	15	–	–	﹤0.01%	861
2021 Q2	$2K	Hold	15	–	–	﹤0.01%	864
2021 Q1	$2K	Hold	15	–	–	﹤0.01%	858
2020 Q4	$3K	Hold	15	–	–	﹤0.01%	775
2020 Q3	$2K	Buy	+15	New	+$2.45K	﹤0.01%	819

Other funds holding FBT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SOS

Silver Oak Securities Jackson, Tennessee $1.37B AUM 20.67% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BFG

Berger Financial Group Plymouth, Minnesota $1.79B AUM 15.72% 1-Year Est. Return

Front Row Advisors's FBT Position: Q3 2023 in Review

Front Row Advisors sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q3 2023, closing a stake of 15 shares — an estimated $2K sold.

Front Row Advisors first reported a position in FBT in Q3 2020 and held it in 12 quarters. The position peaked at $3K in Q4 2020. 242 funds tracked by Wall St. Rank hold FBT as of Q3 2023.

Front Row Advisors reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q3 2023 after selling out during the quarter.
Front Row Advisors sold 15 First Trust NYSE Arca Biotechnology Index Fund shares in Q3 2023, an estimated $2K.
Front Row Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q3 2020 and held it in 12 quarters.
Front Row Advisors's First Trust NYSE Arca Biotechnology Index Fund position peaked at $3K in Q4 2020.
242 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q3 2023.

Based on Front Row Advisors's 13F filing for Q3 2023, filed 15 Nov 2023.